Idexx Laboratories Inc. (NASDAQ:IDXX)‘s stock had its “neutral” rating reissued by investment analysts at Bank of America Corp. in a research note issued to investors on Thursday.
Other analysts have also issued reports about the company. Canaccord Genuity restated a “buy” rating and issued a $120.00 target price on shares of Idexx Laboratories in a research note on Monday, August 22nd. Stifel Nicolaus boosted their price objective on Idexx Laboratories from $120.00 to $125.00 and gave the company a “buy” rating in a research note on Tuesday, August 16th. Zacks Investment Research upgraded Idexx Laboratories from a “hold” rating to a “buy” rating and set a $121.00 price objective on the stock in a research note on Thursday, August 4th. Finally, Northcoast Research upgraded Idexx Laboratories from a “sell” rating to a “neutral” rating in a research note on Wednesday, August 3rd. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Idexx Laboratories has an average rating of “Buy” and a consensus target price of $105.20.
Shares of Idexx Laboratories (NASDAQ:IDXX) traded up 0.77% during mid-day trading on Thursday, hitting $112.73. The stock had a trading volume of 404,716 shares. The firm has a 50 day moving average price of $111.50 and a 200-day moving average price of $93.73. Idexx Laboratories has a 12 month low of $63.48 and a 12 month high of $115.06. The stock has a market cap of $10.09 billion, a P/E ratio of 51.10 and a beta of 0.56.
Idexx Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, August 2nd. The company reported $0.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.12. The firm had revenue of $467 million for the quarter, compared to analyst estimates of $444.83 million. Idexx Laboratories had a negative return on equity of 414.67% and a net margin of 11.94%. The business’s revenue was up 12.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.60 earnings per share. On average, equities research analysts forecast that Idexx Laboratories will post $2.36 EPS for the current year.
In other Idexx Laboratories news, insider Michael J. Phd Williams sold 49,560 shares of the company’s stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $108.94, for a total value of $5,399,066.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Chairman Jonathan W. Ayers sold 60,000 shares of the company’s stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $107.69, for a total value of $6,461,400.00. The disclosure for this sale can be found here. 2.79% of the stock is owned by company insiders.
A number of institutional investors have recently made changes to their positions in the company. Menta Capital LLC acquired a new position in shares of Idexx Laboratories during the first quarter worth $1,143,000. C M Bidwell & Associates Ltd. raised its position in shares of Idexx Laboratories by 1,059.3% in the first quarter. C M Bidwell & Associates Ltd. now owns 46,545 shares of the company’s stock worth $3,645,000 after buying an additional 42,530 shares in the last quarter. BlackRock Group LTD raised its position in shares of Idexx Laboratories by 70.8% in the first quarter. BlackRock Group LTD now owns 130,048 shares of the company’s stock worth $10,185,000 after buying an additional 53,887 shares in the last quarter. BlackRock Inc. raised its position in shares of Idexx Laboratories by 20.7% in the first quarter. BlackRock Inc. now owns 39,545 shares of the company’s stock worth $3,098,000 after buying an additional 6,777 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in shares of Idexx Laboratories by 36.9% in the first quarter. Franklin Resources Inc. now owns 410,613 shares of the company’s stock worth $32,159,000 after buying an additional 110,604 shares in the last quarter. Institutional investors and hedge funds own 91.58% of the company’s stock.
Idexx Laboratories Company Profile
Receive News & Ratings for Idexx Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idexx Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.